Commercialization

Gifthealth CEO Chip Parkinson on the factors accelerating direct-to-patient model adoption, and what's next for the channel.

Four pharma commerce experts revisit their 2026 predictions on dealmaking, patient access and commercialization at the year's midpoint.

Gifthealth's Chip Parkinson says direct-to-patient adoption has accelerated since January, driven by structural, not cyclical, market forces.

How commercial trade groups are shifting from distribution execution to strategic partners shaping market access, launch readiness and commercial performance.

Novo Nordisk’s complaint argues that Lilly's campaigns leave out information about the most effective injectable doses of Wegovy (semaglutide) and Ozempic (semaglutide), a dispute that could reshape how both companies compete for share in the GLP-1 market.

Ramarketing CEO Emma Banks revisits her "year of two halves" outlook, discussing whether 2026 has followed the same pattern and what she expects for H2.

Doceree launched Semmelweis, an AI model built for pharma commercialization, as drugmakers ramp up AI investment in marketing and sales operations.

The models pharma inherited were built for conditions that have changed. A look across the August issue at an industry redesigning itself.

Trutakna's FDA approval for IgAN highlights how patient support programs like TRU SUPPORT coordinate access and adoption in specialty drug launches.

As PBM pressure mounts and formulary bidding wars squeeze manufacturers, a direct access marketplace model offers drug makers a path to compete on efficacy, price and real-world outcomes.

Cash pay is re-emerging as biopharma brands rethink insurance barriers, patient access, and affordability in a fragmented payer market.

As cell and gene therapies move beyond ultra-rare disease indications into broader patient populations, the commercialization infrastructure built around them is due for a fundamental redesign.

Avalere Health analysts map the converging pressures reshaping the drug pricing and distribution landscape ahead of November.

Lilly’s $7B deal for Kelonia aims to turn complex cell therapy into a simple injection, bypassing the slow, costly lab work of current cancer treatments.

Brok Vandersteen explains how life sciences companies can strategically adopt DTP models for better patient access and commercial success.

Kristine McGaughey, vice president of Implementation at ConnectiveRx, shares her insights on timing, strategy, and planning to ensure a smooth therapy launch.

In the first part of his Pharmaceutical Commerce interview, Jay Bregman, founder and CEO of Andel, discusses how employers are exploring direct-to-employer drug purchasing models that bypass traditional pathways.

The current rep model no longer fits. The rep of the future is a strategist, a data-enabled connector, and a trusted ally in improving patient care.

Esperion Therapeutics has entered into a definitive agreement to acquire Corstasis Therapeutics for $75 million upfront and up to $180 million in milestones, integrating Enbumys into its cardiovascular franchise.

The FDA granted accelerated approval to Boehringer Ingelheim’s Hernexeos for first-line HER2-mutant NSCLC following a 44-day review under the National Priority Voucher Program.

A policy change allowing approval of some new drugs based on one adequate and well-controlled study could accelerate development timelines, while raising questions about evidentiary standards and downstream supply chain planning.

The company’s latest preview report projects a guarded rebound for biopharma, as investor confidence returns and M&A activity accelerates.